GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline

British drugmaker GSK moves mRNA flu vaccine to late-stage trials

GSK announced positive results from a mid-stage trial of its mRNA flu vaccine.
The vaccine candidate produced positive immune responses against both A and B flu strains in younger and older adults.
GSK has moved the mRNA flu vaccine to late-stage clinical development.
GSK bought out its partner CureVac in July to enhance its mRNA capabilities.
The trial tested various mRNA formulations to find effective vaccines against flu strains.

British drugmaker GSK has announced that its experimental mRNA flu vaccine has shown positive results in a mid-stage trial, prompting the company to advance the vaccine to late-stage clinical development. The trial demonstrated that the vaccine candidate elicited positive immune responses against both influenza A and B strains in participants of various age groups, including both younger and older adults. This development is part of GSK's broader strategy to enhance its vaccine portfolio, particularly in the wake of patent expirations and declining revenues from existing medications. In July, GSK strengthened its mRNA capabilities by acquiring its partner CureVac's stake in their alliance focused on influenza and COVID-19 vaccine development. The ongoing trials are testing different mRNA formulations to identify the most effective vaccines for better protection against seasonal flu strains.

GSK has reported positive results from a mid-stage trial of its mRNA flu vaccine, leading to its progression to late-stage clinical development. The vaccine demonstrated effective immune responses against influenza A and B strains in both younger and older adults.

GSK Advances mRNA Flu Vaccine to Late-Stage Trials

Score	Value
Scale	7
Novelty	6
Positivity	7
Reliability	8
Actionability	3
Society	6
Journalism	4

GSK Advances mRNA Flu Vaccine to Late-Stage Trials

9/12/2024

[0]Bloomberg.com

[1]Reuters

Highlights